Overexpression of HER2 is found in 25%–30% of breast cancers [8, 9], 17% to 22% of gastric cancers [10, 11], 4% to 6% of non–small cell lung cancers (NSCLC) [12, 13] and also many other kinds of cancers. Here, ERBB2 is linked to breast carcinoma.